...
首页> 外文期刊>The Egyptian Journal of Hospital Medicine >Assessment of Anticardiolipin antibodies, Circulating Lupus anticoagulant, Protein C, Protein S, Antithrombin III &Activated Protein C Resistance and Their Relation to Thomboembolic and Other Clinical Manifestations in Behcet's Disease
【24h】

Assessment of Anticardiolipin antibodies, Circulating Lupus anticoagulant, Protein C, Protein S, Antithrombin III &Activated Protein C Resistance and Their Relation to Thomboembolic and Other Clinical Manifestations in Behcet's Disease

机译:评估Behcet病患者的抗心磷脂抗体,循环性狼疮抗凝剂,蛋白C,蛋白S,抗凝血酶III和活化的蛋白C耐药性及其与血栓栓塞和其他临床表现的关系

获取原文
           

摘要

Background: Venous and arterial thrombosis occurs in patients with Behcet's disease and is associated with significant morbidity and mortality. Studies on a possible association between the occurrence of thrombosis and thrombophilia in patients with this disease have been controversial. The objective of this study was to assess the frequency and clinical relevance of anticardiolipin antibodies (aCL) & other thrombophilic factors and their relationship to thromboembolic & clinical manifestations in Behcet's disease (BD). Materials and methods : IgG, IgM and IgA anticardiolipin antibodies (aCL) isotypes, presence of circulating lupus anticoagulant(LAC), protein C, protein S, antithrombin III & activated protein C resistance were investigated in 25 patients with BD and 25 patients with various rheumatic diseases not known to be associated with venous or arterial thromboembolic phenomena served as controls. Twelve of the patients with BD (48%) had either deep vein thrombosis (8 patients), arterial thromboembolic phenomena (4 patients), or both (2 patients). Results: The IgA aCL elevated in14 (56%) patients with BD compared with one (4%) patient in the control group ( P <0.01). IgG aCL levels were elevated in 13 (52%) patients with Behcet's disease (BD) compared with one (4%) patient in the control group( P <0.01).Also patients with BD do not have decreased protein S, or antithrombin III activity, activated protein C resistance, circulating lupus anticoagulant (LAC), or elevated LgM aCL. No significant differences were found between any variable in both groups. No association between elevated IgMaCL levels and venous or arterial thrombosis and no statistical correlation was found between any factor and clinical manifestations of the disease. Conclusion: A significant number of patients have elevated levels of IgA& IgG aCL but they are not associated with venous or arterial thrombosis. These results do not suggest a primary role for aCL in BD and do not support the role of coagulation abnormalities in the pathogenesis of thromboembolic complications of Behcet's disease but suggest vascular inflammation as the main pathogenetic event in the vascular lesions in Behcet's disease
机译:背景:贝塞特氏病患者发生静脉和动脉血栓形成,并伴有明显的发病率和死亡率。关于该病患者血栓形成与血栓形成之间可能存在的关联的研究一直存在争议。这项研究的目的是评估抗心磷脂抗体(aCL)和其他血栓形成因素的频率和临床相关性,以及它们与Behcet病(BD)的血栓栓塞和临床表现的关系。材料和方法:在25例BD患者和25例不同的BD患者中研究了IgG,IgM和IgA抗心磷脂抗体(aCL)的同种型,循环性狼疮抗凝剂(LAC),蛋白C,蛋白S,抗凝血酶III和活化的蛋白C抵抗已知与静脉或动脉血栓栓塞现象无关的风湿性疾病为对照。 BD患者中有十二名(48%)患有深静脉血栓形成(8例),动脉血栓栓塞现象(4例)或两者(2例)。结果:BD患者中14例(56%)IgA aCL升高,而对照组中1例(4%)(P <0.01)。与对照组相比,白塞氏病(BD)患者中13名(52%)患者的IgG aCL水平升高(4%)(P <0.01).BD患者也没有蛋白S或抗凝血酶III降低活性,活化的C蛋白抗性,循环性狼疮抗凝剂(LAC)或升高的LgM aCL。两组中的任何变量之间均未发现显着差异。 IgMaCL水平升高与静脉或动脉血栓形成之间没有关联,并且该病的任何因素与临床表现之间均未发现统计学相关性。结论:大量患者的IgA和IgG aCL水平升高,但与静脉或动脉血栓形成无关。这些结果并不表明aCL在BD中起主要作用,也不支持凝血异常在Behcet病的血栓栓塞性并发症的发病机理中的作用,但提示血管炎症是Behcet病血管病变的主要致病事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号